App-Quantinova.ai

Impact of Induction Chemotherapy and Primary CNS Prophylaxis on Outcomes in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements (HGBL-DH/TH) or HGBL-NOS: An International Multi-Center Retrospective Analysis

John R Balendra - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

N/A

Encouraging Clinical Outcomes for Lymphoma Patients Participating in Early Phase Clinical Trials in the Current Era: A Single Institution and a Global Perspective

Jenny O'Nions - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

N/A

Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience

Vasiliki Michalarea - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B cell lymphomas

N/A

Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial

Michael W. Deininger - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Bosutinib

An Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase Chronic Myeloid Leukemia

Bogdan Muresan - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Bosutinib

DNA-Based Digital PCR for the Quantification of Residual Disease in CML — Sensitivity or Specificity?

Mary Alikian - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Nilotinib

Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial

Tim H. Brummendorf - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Bosutinib

Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients

Simone Claudiani - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Bosutinib

Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis

Jeong-Ok Lee - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Interferon

Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy

Ekaterina Chelysheva - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

N/A

Clinical Intervention Using NGS-Based Kinase Domain Mutation Testing in CML Patients

Aytug Kizilors - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Nilotinib

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Jean-Jacques Kiladjian - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Polycythemia vera

Hydroxyurea

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Allison Gathany - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

N/A

Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work

Ianotto Jean-Christophe - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Hydroxycarbamide

Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide

Onima Chowdhury - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Pomalidomide

Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Ruben A. Mesa - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Essential thrombocythemia

Peginterferon alfa-2a

Pooled Analyses of Total Symptom Score (TSS) Responses in Patients with Myelofibrosis (MF) Treated with Pacritinib (PAC) Vs Best Available Therapy (BAT) in Phase 3 Studies (PERSIST-1, PERSIST-2)

Ruben A. Mesa - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thrombocytopenia

Ruxolitinib phosphate

Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges

Zhenya Senyak - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

EZH2

Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms

Tiziano Barbui - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

N/A

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Krisstina L. Gowin - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

N/A

Filters

45280 Abstracts